Exscientia to screen nearly every known approved and investigational drug - 15,000 clinical molecules - against key COVID-19 drug targets to progress rapid treatments and generate data to seed design of superior molecules 

Exscientia announces joint initiative to identify COVID-19 drugs with Diamond Light Source and Scripps Research 

Coverage of our company in Financial Times newspaper

Financial Times : 

Read the article detailing Exscientia's work on the first AI-designed drug 
to enter clinical trials.

Sumitomo Dainippon Pharma and Exscientia Joint Development  New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Trial

Exscientia appoints Dr. David Hallett as Chief Operating Officer

Exscientia appoints Dr. David Hallett as Chief Operating Officer as company positions for further growth

AI Design of new therapeutics for cardiovascular and oncology disease

Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery

AI Design enables new bispecific small molecule modality

Sanofi Exercises option on Exscientia-designed bispecific small molecule for treatment of immunological conditions

Joint venture will initiate drug discovery programs targeting rare diseases using AI

Exscientia enters broad rare disease drug discovery collaboration with Rallybio

Firm enters a multi-target AI drug discovery partnership with initial focus on oncology

Exscientia expands international collaborations with Shanghai-headquartered GT Apeiron Therapeutics

Exscientia achieves molecule discovery milestone as part of GSK collaboration 

Exscientia continues expansion with establishment of a subsidiary in Japan to target the pharmaceutical market across Asia

Exscientia がアジアの創薬マーケットを狙った子会社を日本に設立

Celgene and Exscientia enter 3-year AI drug discovery collaboration focused on accelerating drug discovery in oncology and autoimmunity

Exscientia hires director of data engineering to scale up its AI drug discovery platform

Exscientia to receive up to CHF 67 million in upfront payments, research support and milestone payments in discovery collaboration with Roche

Exscientia initiates sixth AI drug discovery partnership

NEW INVESTORS CELGENE CORPORATION AND GT HEALTHCARE CAPITAL PARTNERS JOIN SERIES A INVESTOR EVOTEC.

Exscientia raises US $26 million in series B financing round to accelerate scaling as the leading AI drug discovery company

Exscientia builds "full stack" AI-driven drug discovery capabilities through acquisition of kinetic discovery

Facilities in the Schrödinger Building to bring together AI experts and biologists

Leading AI-driven drug discovery company Exscientia expands to the Oxford Science Park

Exscientia appoints Georgy Egerov as chief financial officer bringing significant capital markets and strategic development expertise to support business growth

Exscientia to present at Numis T500 conference 2018 - linking innovative companies with investors

Publication including Exscientia's chief chemist Andy Bell, describes a potential new treatment for the common cold

Exscientia appoints Alex Snow, founder of Oxford innovation sciences and former CEO of Lansdowne Partners, as deputy chairman

Exscientia opens new office in Oxford as part of plan for rapid growth and expansion

Exscientia wins science and technology business of the year

Exscientia wins best emerging biotech company award at OBN Annual Awards 2017

Evotec invests in Exscientia to advance AI-driven drug discovery

GSKが指定する最大10の創薬標的タンパク質に絞った前臨床創薬共同研究

EXSCIENTIAはGSKと戦略的共同研究契約を締結

Pre-clinical collaboration focused on up to 10 targets nominated by GSK

Exscientia enters strategic drug discovery collaboration with GSK

Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is delighted to announce that its Chief Executive Officer Andrew Hopkins has been named Chemistry World ‘Entrepreneur of the Year’. Chief Technology Officer Jérémy Besnard also won the ‘Rising Star in Industry’ Award at the Chemistry Means Business 2017 Awards, hosted by the UK Royal Society of Chemistry in Manchester this week.

Exscientia wins two awards at Royal Society of Chemistry's 'Chemistry Means Business' Awards 2017

Initiates collaboration to develop bispecific-small-molecule drugs

Exscientia announces EUR250 million collaboration for a multiple-product development and licence option agreement with Sanofi

二重特異性低分子薬剤の共同研究開発を開始

エクセンシアが複数製品開発およびライセンスオプション契約で サノフィとの2億5000万ユーロの提携を発表

Exscientia announces progress in immuno-oncology collaboration with Evotec presented at AACR

Evotec and Exscientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics

Exscientia names young business of the year

Exscientia one of three finalists for best emerging UK biotech company at the OBN Awards

Exscientia Ltd, reaches first delivery milestone in collaboration with Sumitomo Dainippon Pharma Co., Ltd.

Exscientia CEO Andrew Hopkins wins prestigious BBSRC innovator award

Andrew Hopkins, CEO of Exscientia, is awarded Scottish Enterprise Life Science Business prize

Exscientia partners with Sunovion Pharmaceuticals inc. to research new medicines for psychiatric disorders.

Recruitment of Andy Bell, co-inventor of Sildenafil, to head up Exscientia chemistry team

Bispecific drug discovery agreement with Sumitomo Dainippon Pharma Co., Ltd

BBSRC chief executive Douglas Kell highlights Exscientia approach for advancement of complex drug design

Exscientia strengthens drug design capability with key appointments

Exscientia establishes collaboration with Janssen research & development

Bi-specific enzyme inhibitors deal with top 10 US pharma

Exscientia signs proof-of-concept deal with Sunovion Inc. to discover 'bi-specific' compounts for psychiatric disease